https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-atezolizumab-with-or-without-tiragolumab-for-oesophageal-cancer-skyscraper-07
This trial is looking at giving atezolizumab with or without tiragolumab after chemoradiotherapy.
triallookingatezolizumabwithouttiragolumab
https://pubmed.ncbi.nlm.nih.gov/32576590/
The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II...
tiragolumabimpressesmultipletrials
https://www.pharmaceutical-technology.com/data-insights/tiragolumab-roche-net-present-value/?utm_source=lgp5-npv&utm_medium=24-329398&utm_campaign=recommended-articles-pi
Tiragolumab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomatiragolumabgenentechusaesophageal
https://stanfordhealthcare.org/trials/a/NCT04513925.html
Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more.
studyatezolizumabtiragolumabcompareddurvalumab